Catch up on insights into the global development of breast cancer treatments in the global spotlight.
|Videos|May 1, 2017
Dr. Janni on the Future of Treatments for HER2-Positive Breast Cancer
Author(s)Wolfgang Janni, MD, PhD
Wolfgang Janni, MD, PhD, University of Ulm, discusses the future of treatments for patients with HER2-positive breast cancer.
Advertisement
Wolfgang Janni, MD, PhD, University of Ulm, discusses the future of treatments for patients with HER2-positive breast cancer.
According to Janni, the APHINITY trial, is one of the trials that many are still excited about regarding treatments for HER2-positive breast cancer.
In terms of new agents, Janni states that it will be interesting to see data on other targeted agents such as CDK4/6 inhibitors in the HER2-positive setting. There is interesting data suggesting that this could be beneficial to patients.
Advertisement
Related to this article
Read our recap of top phase 1 and 2 breast cancer data highlights that may lead to further clinical research and developments.
Read our recap of the top phase 3 breast cancer data announcements and highlights that may make waves in the future of breast cancer management.
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Read a refresh of breast cancer FDA news from June 2026, including several practice-changing approvals and the granting of priority review to a SERD.
The FDA approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.
The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
2
NMPA Accepts Toripalimab Plus Chemotherapy Application for Expanded Stage II-III NSCLC Use
3
Ivonescimab Plus Chemotherapy Sustains OS Benefit Across Western and Asian Patients in Pretreated EGFR-Mutated NSCLC
4
Dr Patel on the Unmet Need in EGFR+ Transformed Small Cell Lung Cancer
5